Results 61 to 70 of about 8,348 (154)

Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients

Global & Regional Health Technology Assessment, 2017
Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patientsBackgroundA one-year cost analysis was conducted to estimate the impact from the perspective of the Italian National Health Service (
Roberto Ravasio, Mauro Maresca, Barbara Busà, Benedetto Maurizio Celesia   +3 more
doaj   +1 more source

Maraviroc and raltegravir [PDF]

British Journal of Clinical Pharmacology, 2009
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

Brazilian Journal of Infectious Diseases, 2010
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Daria J. Hazuda, PhD
doaj   +1 more source

Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy

Retrovirology, 2010
Background In this study we successfully created a new approach to ART in SIVmac251 infected nonhuman primates. This drug regimen is entirely based on drugs affecting the pre-integration stages of replication and consists of only two nucleotidic ...
Greenhouse Jack, Yalley-Ogunro Jake, Chirullo Barbara, Iraci Nunzio, Collins Matt, Barreca Maria, Norelli Sandro, Lewis Mark G, Titti Fausto, Garaci Enrico, Savarino Andrea   +10 more
doaj   +1 more source

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity

European Journal of Medical Research, 2010
Background in HIV-infected patients with HCV-related chronic hepatitis, liver impairment and drug toxicity may substantially reduce the number of possible therapeutic options.
Ortu F, Weimer LE, Floridia M, Manconi PE   +3 more
doaj   +1 more source

ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA

Фармакоэкономика, 2015
The purpose of the work performed was assessment of cost efficiency of Raltegravir within the schemes of antiretroviral therapy as compared to the schemes on the basis of drugs from the group of protease inhibitors with adult patients with Type 1 HIV ...
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov   +4 more
doaj   +1 more source

Long-term efficacy and safety of raltegravir in the management of HIV infection

Infection and Drug Resistance, 2014
Michelle D Liedtke, C Ryan Tomlin, Staci M Lockhart, Misty M Miller, R Chris Rathbun Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Raltegravir is ...
Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC   +4 more
doaj  

Physiologically Based Pharmacokinetic Modelling of UGT Substrate Drugs Lamotrigine and Raltegravir during Pregnancy

Future Pharmacology
Pregnancy is associated with various physiological changes that can significantly impact the disposition of drugs. To further the insight into how pregnancy affects the pharmacokinetics of drugs at different stages, clinical studies can be simulated ...
Monika Berezowska, Paola Coppola, Venkatesh Pilla Reddy, Pradeep Sharma   +3 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs

Качественная клиническая практика, 2018
Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background ...
Y. I. Ashikhmin, D. Yu. Belousov
doaj